NORWALK, Conn.--(BUSINESS WIRE)--April 12, 2005-- Industry Leaders to Address Safety and Toxicity Concerns at PharmaDiscovery 2005 Costs associated with populating the pharmaceutical industry’s drug pipelines are increasing steadily. Success demands that pharmaceutical research link to the biology of the human system as closely as possible in the drug candidacy process. With this, more and more drug companies are eagerly searching for ways to fill these pipeline voids and are now exploring new in vivo models to base their pre-clinical drug development. World leading scientists and life science companies will gather for PharmaDiscovery 2005, an Elsevier event, May 10-12, at the Washington, D.C. Convention Center to tackle some of the most pressing issues surrounding drug development including trends like emerging in vivo models.
